Home Capital Broker's Calls

Hyphens Pharma gets a 'buy' from SAC as it looks to undertake more R&D initiatives

Amala Balakrishner
Amala Balakrishner8/27/2021 2:18 PM GMT+08  • 2 min read
Hyphens Pharma gets a 'buy' from SAC as it looks to undertake more R&D initiatives
SAC Capital is maintaining its “buy” call and target price of 37 cents on pharmaceutical distributor Hyphens Pharma.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SAC Capital is maintaining its “buy” call and target price of 37 cents on pharmaceutical distributor Hyphens Pharma.

The price translates to an FY21 Price-to-earnings (P/E) of 17.5x and is expected to give the counter a 23.3% upside from its 30 cent price, analyst Tracy Lim writes in a Aug 24 report.

Her move follows the company’s revenue for 1HFY21 ended June which was “in line with our forecasts”.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.